Chester County News and Community Website
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved blinatumomab (Blincyto, Amgen Inc.) for both adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative …
FDA Approves Blinatumomab for Advanced Leukemia Treatment Read More
PHILADELPHIA, PA — EpiVario Inc., a biotechnology firm specializing in neuroepigenetics to treat addiction disorders, announced a significant licensing deal with ReEngage Therapeutics. The agreement involves several of EpiVario’s small …
EpiVario Licenses Cancer-Fighting Compounds in Strategic Move Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical trial for CTIM-76, a pioneering …
FDA Clears Context Therapeutics to Begin Trial for Novel Cancer Therapy Read More
WARRINGTON, PA — Windtree Therapeutics, Inc., a leading player in the biopharmaceutical industry, announced this week its acquisition of certain assets from Varian Biopharmaceuticals, Inc., a move that amplifies the …
Windtree Therapeutics Takes a Bold Stride in Oncology with Varian Assets Acquisition Read More
HORSHAM, PA — Johnson & Johnson recently announced that the U.S. Food and Drug Administration (FDA) has granted approval for a reduced dosage frequency of its drug TECVAYLI® (teclistamab-cqyv) in …
FDA Greenlights Reduced Dosing Frequency for Johnson & Johnson’s TECVAYLI Read More
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a leading biotech firm specializing in cancer therapies, recently announced its plan to purchase a trove of antibody-related assets from Atreca, Inc. (Nasdaq: …
Immunome Set to Acquire Atreca’s Antibody-Related Assets in a Move to Revolutionize Cancer Therapies Read More
The U.S. Food and Drug Administration recently approved Tibsovo (ivosidenib)Â for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as …
FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes Read More